Adaptive designs: When are they sensible?
|
|
- Bethany Chandler
- 5 years ago
- Views:
Transcription
1
2
3 Adaptive designs: When are they sensible? Janet Wittes Statistics Collaborative, Inc. Sensible Guidelines May 2012
4 The pitch Clinical trials are too rigid There are new classes of designs More ethical More efficient Adaptations saves money, time, etc. But, we need to be adaptive by design
5 Jerry Cornfield s admonition The statistician functions as a devil s advocate against the admission of new evidence, and, in this capacity, has an important influence on the quality and cogency of the evidence submitted. The investigator must pay close attention to this advocate, but it is his and not the advocate s responsibility to decide when he must stop listening. Am J of Mental Deficiency 64: (1959)
6 What s wrong with the pitch Not really so new
7 What s wrong with the pitch Not really so new Doesn t always save time or money May be very much less efficient I don t know what ethics means
8 What s wrong with the pitch Not really so new Doesn t always save time or money May be very much less efficient I don t know what ethics means Adaptive by design good in general Don t always need to design up front Should Columbus have declared the islands India?
9 Four kinds of adaptations Operational Fix nuisance parameters (internal pilot) Change hypothesis: external data and thoughts Change hypothesis: internal data
10 Operational Titrating the design Adding and dropping centers Encouraging adherence to study protocol Changing entry criteria
11 Not really so new Molière s Bourgeois Gentilhomme Good Heavens! For more than forty years I have been speaking prose without knowing it. M. Jourdain
12 Four kinds of adaptations Operational Fix nuisance parameters (internal pilot) Change hypothesis: external data and thoughts Change hypothesis: internal data
13 External vs. internal pilots External pilot Do a prior study prior to real study Use knowledge gained to design real study Internal pilot (aka adaptive design ) Start a real study Tweak it on basis of early data
14 External pilot studies Feasibility Questionnaires & instruments Assays Etc. Parameters Variances Event rates
15 The paranoid s view of external pilots Pilot populations: small, relatively homogeneous Therefore estimates not reliable Pilot variances too small Pilot rates and hazards are not accurate Safety: can only see frequent events Efficacy: only hope - look at surrogates & markers
16
17 Internal pilot Start study with unanswered design questions What is the variance? The drop-out rate? The (pooled) cross-over rate? The event rate? The effect size? Look at early data and change design parameters
18 The variance or rate unknown Sample size proportional to σ 2 Part-way recalculate sample size using new s 2 Worries Blinded/unblinded? When should we look? Too early, our s 2 is too imprecise Will it preserve Type I error rate?
19 Nuisance parameter (s 2, p, ) unknown Blinded/unblinded: Methods for both When to look: ~ ½ way is not a bad time Preserve Type I error rate? Methods available Conclusion: methods not controversial My experience: FDA and EMA are fine with this Hard to include in grant because of time
20 Four kinds of adaptations Operational Fix nuisance parameters (internal pilot) Change hypothesis: external data and thoughts Change hypothesis: internal data
21 Change the 1 outcome or analysis SHARP originally set out to assess the effects of lowering cholesterol on the risk of major vascular events, defined as major atherosclerotic events plus other cardiac causes of death and strokes due to bleeding. But, whilst the trial was ongoing, new information became available from other completed studies that suggested that lowering cholesterol might have little effect on these additional events. Before breaking the trial s code, therefore, the independent Steering Committee decided that analyses of major atherosclerotic events would provide the most valuable information to patients and doctors. This change was described in a paper that was published in a leading medical journal before the trial s code was broken. Taking the combination of ezetimibe and simvastatin long-term reduced the risk of heart attacks, strokes and operations to open blocked arteries by about one quarter in people with chronic kidney disease, irrespective of the severity of their disease
22 Changing primary outcome Do with trepidation There is a certain incertitude concerning the primary endpoint (apparently changed by the Steering committee before the trial ended but this change was not endorsed by the sponsor).
23 Other similar changes. Change method of analysis E.g., way of handling missing Switch from change score to longitudinal analysis
24 Four kinds of adaptations Operational Fix nuisance parameters (internal pilot) Change hypothesis: external data and thoughts Change hypothesis: internal data on effect size
25 Effect size-start with a hypothesized Frequentist Look part-way through (define when; infrequent) Calculate observed and recalculate sample size Bayesian Look part-way through (can be often) Calculate predictive power Decide whether to stop or add more
26 Problems with frequentist approach The methods can be very inefficient Data after the adjustment is downweighted Downweighting can be serious Early data imprecise Does have a clinical meaning? If we have chosen rationally, is smaller ok?
27 Problems with Bayesian approach In ordinary sequential If you don t cross boundary, you can t declare success If you do cross boundary, you don t have to stop Then you recoup you re α In Bayes, must you follow the rules? True Bayesians: no FDA: yes My experience: Bayes adaptation black boxy
28 So, the dilemma External pilot studies (Phase 2) are scientifically Important and necessary But boring Hard to fund Internal pilot studies Effective in tweaking parameters Not always accepted
29 The interesting methods (i.e., the ones popularly called adaptive ) Fundamentally change the hypothesis If we believe in Δ Are statistically inefficient Even if the new estimate is correct But it s subject to a lot of variability Require extremely careful protection of the blind
30 Conclusions I Failure to adapt when necessary risks failure Operational: doesn t need plan Nuisance parameters: probably need intent Response to outside data: cannot have plan
31 Conclusions II Failure to adapt when necessary risks failure Operational: doesn t need plan Nuisance parameters: helps to have plan Response to outside data: cannot have plan Adapting on the basis of observed effect Adds power at the expense of Large increase in sample size Changing hypothesis
32 Conclusions from a Neanderthal The questions we are asking are important! Many adaptive designs trade speed for precision We should be aiming for reasonable precision A good understanding of risks and benefits Adaptive trials are VERY operationally complex
Fundamental Clinical Trial Design
Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003
More informationIntegrating Effectiveness and Safety Outcomes in the Assessment of Treatments
Integrating Effectiveness and Safety Outcomes in the Assessment of Treatments Jessica M. Franklin Instructor in Medicine Division of Pharmacoepidemiology & Pharmacoeconomics Brigham and Women s Hospital
More information4/14/2016. Take ownership of the care - This is my patient!
Guidelines and Training in how to be a Emergency Health Professional NAVIGATOR 2016 Paul Stiegler MD FACEP Medical Director EMD Dane County PSCC Onstar LLC Take ownership of the care - This is my patient!
More informationSample Size Considerations. Todd Alonzo, PhD
Sample Size Considerations Todd Alonzo, PhD 1 Thanks to Nancy Obuchowski for the original version of this presentation. 2 Why do Sample Size Calculations? 1. To minimize the risk of making the wrong conclusion
More informatione.com/watch?v=hz1f yhvojr4 e.com/watch?v=kmy xd6qeass
What you need to know before talking to your statistician about sample size Sharon D. Yeatts, Ph.D. Associate Professor of Biostatistics Data Coordination Unit Department of Public Health Sciences Medical
More informationSample Size, Power and Sampling Methods
Sample Size, Power and Sampling Methods Mary Ann McBurnie, PhD Senior Investigator, Kaiser Permanente Center for Health Research Steering Committee Chair, Community Health Applied Research Network (CHARN)
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationBayesian and Frequentist Approaches
Bayesian and Frequentist Approaches G. Jogesh Babu Penn State University http://sites.stat.psu.edu/ babu http://astrostatistics.psu.edu All models are wrong But some are useful George E. P. Box (son-in-law
More informationThe Conference That Counts! March, 2018
The Conference That Counts! March, 2018 Statistics, Definitions, & Theories The Audit Process Getting it Wrong Practice & Application Some Numbers You Should Know Objectivity Analysis Interpretation Reflection
More informationStatistical Considerations in Pilot Studies
Statistical Considerations in Pilot Studies Matthew J. Gurka, PhD Professor, Dept. of Health Outcomes & Policy Associate Director, Institute for Child Health Policy Goals for Today 1. Statistical analysis
More informationST440/550: Applied Bayesian Statistics. (10) Frequentist Properties of Bayesian Methods
(10) Frequentist Properties of Bayesian Methods Calibrated Bayes So far we have discussed Bayesian methods as being separate from the frequentist approach However, in many cases methods with frequentist
More informationRole Playing & Goal Setting
ACTIVITY OUTLINE Role Playing & Goal Setting These activities will allow members to: Learn how to set goals and develop team-building skills. Practice active listening. Think through problems to find solutions.
More informationBreast Cancer Network Australia Breast Care Nurse Breast Reconstruction Survey September 2011
Breast Cancer Network Australia Breast Care Nurse Breast Reconstruction Survey September 2011 This project was undertaken with the support of Cancer Australia through the Building Cancer Support Networks
More informationNONPROFIT CONFLICT COMMUNICATION SKILLS
NONPROFIT CONFLICT COMMUNICATION SKILLS Elise M. Chambers, Esq. Program Director elise@crcminnesota.org 612-813-3206 TODAY, WE LL Get a crash course: Earn a PhD in Conflict Resolution Theory in 10 minutes
More informationStatistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials
Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials Dominik Heinzmann, PhD Global Development Team Leader HER2 Associate Director
More informationCalculating Risk for Primary Prevention of Cardiovascular Disease (CVD)
Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North
More informationFrequently asked questions in response to ABC Catalyst report about cholesterol and medications
Frequently asked questions in response to ABC Catalyst report about cholesterol and medications Quick links to the evidence available: The Heart Foundation s guideline for the management of primary prevention
More informationMichael J. Negrete, PharmD Chief Executive Officer
Making the Most of Your Medications Michael J. Negrete, PharmD Chief Executive Officer 2 Drivers of Increasing Drug Spending Three main factors: Price Increases 24% Drug Mix 28% 3 Utilization 48% Aging
More informationChoose a fertility clinic: update
Choose a fertility clinic: update Strategic delivery: Setting standards Increasing and informing choice Demonstrating efficiency economy and value Details: Meeting Authority Agenda item 10 Paper number
More informationHigh blood pressure affects 1 in every 3 adults
High blood pressure affects 1 in every 3 adults What does high blood pressure mean for you? What can you do to take control? High blood pressure raises your risk of a stroke or heart attack. You can lower
More informationSample size for clinical trials
British Standards Institution Study Day Sample size for clinical trials Martin Bland Prof. of Health Statistics University of York http://martinbland.co.uk/ Outcome variables for trials An outcome variable
More informationLecture Notes Module 2
Lecture Notes Module 2 Two-group Experimental Designs The goal of most research is to assess a possible causal relation between the response variable and another variable called the independent variable.
More informationProblem Situation Form for Parents
Problem Situation Form for Parents Please complete a form for each situation you notice causes your child social anxiety. 1. WHAT WAS THE SITUATION? Please describe what happened. Provide enough information
More informationProf. David Wheeler Centre for Nephrology Royal Free Campus University College London Medical School London, UK. Slide 1
LDL-CHOLESTEROL AND CV RISK IN CKD: EPIDEMIOLOGY VS. CLINICAL TRIALS David Wheeler, London, UK Chairs: Maurice Laville, Lyon, France Erling B. Pedersen, Holstebro, Denmark Prof. David Wheeler Centre for
More informationObjectives. Quantifying the quality of hypothesis tests. Type I and II errors. Power of a test. Cautions about significance tests
Objectives Quantifying the quality of hypothesis tests Type I and II errors Power of a test Cautions about significance tests Designing Experiments based on power Evaluating a testing procedure The testing
More informationDiscussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK
Discussion Meeting for MCP-Mod Qualification Opinion Request Novartis 10 July 2013 EMA, London, UK Attendees Face to face: Dr. Frank Bretz Global Statistical Methodology Head, Novartis Dr. Björn Bornkamp
More informationOne slide on research question Literature review: structured; holes you will fill in Your research design
Topics Ahead Week 10-11: Experimental design; Running experiment Week 12: Survey Design; ANOVA Week 13: Correlation and Regression; Non Parametric Statistics Week 14: Computational Methods; Simulation;
More informationAMS 5 EXPERIMENTAL DESIGN
AMS 5 EXPERIMENTAL DESIGN Controlled Experiment Suppose a new drug is introduced, how do we gather evidence that it is effective to treat a given disease? The key idea is comparison. A group of patients
More informationHow is ethics like logistic regression? Ethics decisions, like statistical inferences, are informative only if they re not too easy or too hard 1
How is ethics like logistic regression? Ethics decisions, like statistical inferences, are informative only if they re not too easy or too hard 1 Andrew Gelman and David Madigan 2 16 Jan 2015 Consider
More informationP values From Statistical Design to Analyses to Publication in the Age of Multiplicity
P values From Statistical Design to Analyses to Publication in the Age of Multiplicity Ralph B. D Agostino, Sr. PhD Boston University Statistics in Medicine New England Journal of Medicine March 2, 2017
More informationBest Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationDesign and analysis of clinical trials
Design and analysis of clinical trials Lecture 3 1.Basic Design Considerations 2.Sample Size determinationa 3.Randomization 2018-01-31 Previous Lectures Definition of a clinical trial The drug development
More informationHow to design a pilot study
Wikimedia Commons 27 Sokoljan Creative Commons SA 3. Unported How to design a pilot study extrapolation of results Helmut Schütz BioBriges 217 Prague, 2 21 September 217 1 Review of Guidelines Minimum
More informationPerfect Bayesian Equilibrium
Perfect Bayesian Equilibrium Econ 400 University of Notre Dame Econ 400 (ND) Perfect Bayesian Equilibrium 1 / 27 Our last equilibrium concept The last equilibrium concept we ll study after Nash eqm, Subgame
More informationTitle: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study.
Manuscript type: Invited Commentary: Title: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study. Authors: David C Wheeler 1 and Bertram
More informationHead Up, Bounce Back
Head Up, Bounce Back Resilience in YOUth Presented By: Kyshon Johnson, V.P. Youth M.O.V.E. Philadelphia YOUTH M.O.V.E. PHILADELPHIA We are Youth MOVE Philadelphia. We work under the City of Philadelphia
More informationTip sheet. A quick guide to the dos and don ts of mental health care and inclusion. 1. Ask questions. Practical tips
A quick guide to the dos and don ts of mental health care and inclusion Much of the rejection felt by those in church with mental health problems comes from accidental actions and words, delivered with
More informationGetting a New Kidney UHN. Information for patients and families. Is a kidney transplant right for me? Read this booklet to learn:
Getting a New Kidney UHN Information for patients and families Read this booklet to learn: about kidney transplants who can be donors how to start the transplant process how long the process might take
More informationThinking about giving up. Booklet 2
Thinking about giving up Booklet 2 This booklet is written for people who are trying to make up their mind about giving up smoking. A lot of people who smoke have done so for a long time, and like smoking.
More informationSis for. smoking and pregnancy. Don t give up giving up. textphone
Don t give up giving up. For friendly, practical advice on giving up smoking and where you can find help close to home, call the NHS Pregnancy Smoking Helpline 0800 169 9 169 textphone 0800 169 0 171 Sis
More informationLUNG CANCER CLINICAL TRIALS
UNDERSTANDING SERIES LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT THE BASICS ABOUT CLINICAL TRIALS WITH MORE INFORMATION YOU CAN MAKE BETTER CHOICES. The decision
More informationMEDICINES ADHERENCE The Role of the Pharmacist
BROUGHT TO YOU BY MEDICINES ADHERENCE The Role of the Pharmacist Developed by Pfizer 15 May, 2017 This learning module is intended for UK healthcare professionals only. Job code; PP-GEP-GBR-0682. Date
More informationNational Inspection of services that support looked after children and care leavers
National Inspection of services that support looked after children and care leavers Introduction Children and young people that are looked after and those leaving care need the best support possible. Support
More informationStatistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute
Statistical Challenges for Novel Technologies Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute ISCTM 2016 Autumn Conference, Philadelphia, PA 27 September
More informationUnderstanding Pain. Teaching Plan: Guidelines for Teaching this Lesson
Understanding Pain Teaching Plan: Guidelines for Teaching this Lesson Lesson Overview This one-hour lesson plan is about pain and how your workers should respond to and care for residents with pain. You
More informationReview: Conditional Probability. Using tests to improve decisions: Cutting scores & base rates
Review: Conditional Probability Using tests to improve decisions: & base rates Conditional probabilities arise when the probability of one thing [A] depends on the probability of something else [B] In
More informationFMEA AND RPN NUMBERS. Failure Mode Severity Occurrence Detection RPN A B
FMEA AND RPN NUMBERS An important part of risk is to remember that risk is a vector: one aspect of risk is the severity of the effect of the event and the other aspect is the probability or frequency of
More informationMTAT Bayesian Networks. Introductory Lecture. Sven Laur University of Tartu
MTAT.05.113 Bayesian Networks Introductory Lecture Sven Laur University of Tartu Motivation Probability calculus can be viewed as an extension of classical logic. We use many imprecise and heuristic rules
More informationReliability and Validity checks S-005
Reliability and Validity checks S-005 Checking on reliability of the data we collect Compare over time (test-retest) Item analysis Internal consistency Inter-rater agreement Compare over time Test-Retest
More informationEuropean Federation of Statisticians in the Pharmaceutical Industry (EFSPI)
Page 1 of 14 European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) COMMENTS ON DRAFT FDA Guidance for Industry - Non-Inferiority Clinical Trials Rapporteur: Bernhard Huitfeldt (bernhard.huitfeldt@astrazeneca.com)
More information3. Fixed-sample Clinical Trial Design
3. Fixed-sample Clinical Trial Design Review of course organization 1. Scientific Setting 1.1 Introduction and overview 1.2 Phases of investigation 1.3 Case Study 2. From scientific setting to statistical
More informationPRESS RELEASE. November is Diabetes Awareness Month Severity/Epidemic and Risk Factors of Diabetes
November 7, 2012- (Part 1 in a series of 5) November is Diabetes Awareness Month Severity/Epidemic and Risk Factors of Diabetes Data released from the American Diabetes Association have found almost 26
More informationGoldsmith. Marshall. FEEDFORWARD Coaching For Your Future. Coaching For Your Future. MMIX ChartHouse Learning. All Rights Reserved. What Is It?
FOR PREVIEW ONLY Marshall Goldsmith Table of Contents.............................................. 2 Get 360 Feedback...3 Pick a Behavior...4 Respond.......................................... 4 Involve...6
More informationGROWING TOGETHER FOR THE FUTURE
Proceedings from the Ontario Dementia Network Conference October 20, 2003 Toronto Moving Dementia Networks Forward & Provincial Advice to the Dementia Networks Advisory Committee How do we ensure at a
More informationPower & Sample Size. Dr. Andrea Benedetti
Power & Sample Size Dr. Andrea Benedetti Plan Review of hypothesis testing Power and sample size Basic concepts Formulae for common study designs Using the software When should you think about power &
More informationFacilitated Discussion Notes Autism and Mental Health May 12, 2014
Facilitated Discussion Notes Autism and Mental Health May 12, 2014 Below are notes distilling the comments made by participants during a Facilitated Discussion of this topic. Generally, the comments are
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationPatient-reported outcome
Patient-reported outcome How does it compare to EORTC QOL assessment in EMBRACE? Pilot testing in Vienna Kathrin Kirchheiner, Elke Dörr EORTC Answer categories not precise It remains unclear if frequency,
More informationComments from AstraZeneca UK Ltd
13 June 2007 NICE HTA: Ezetimibe for the treatment of primary (heterozygous familial and nonfamilial) hypercholesterolemia Appraisal Consultation Document (ACD) Many thanks for providing the ACD for the
More informationLiving well today...32 Hope for tomorrow...32
managing diabetes managing managing managing managing managing managing diabetes Scientific research continually increases our knowledge of diabetes and the tools to treat it. This chapter describes what
More informationPatient and Family Engagement and Retention. Care Manager Role. Who is on the recruitment/engagement team? General Recruitment Challenges
Patient and Family Engagement and Retention Announcement from Archstone Foundation Rita Haverkamp, MSN, PMHCNS BC, CNS Expert Care Manager and AIMS Center Trainer Collaborative Care Team Approach Care
More informationChallenges and Opportunities: How to increase desire for insulation. ICAA September 29, 2016
Challenges and Opportunities: How to increase desire for insulation ICAA September 29, 2016 Our Vision: Every home & building in America is energy responsible and sustainability is ordinary. We create
More informationCLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM
CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM Principles of Decision Making Knowing the patient s true state is often unnecessary Does my patient
More informationHelmut Schütz. Statistics for Bioequivalence Pamplona/Iruña, 24 April
Sample Size Estimation Helmut Schütz Statistics for Bioequivalence Pamplona/Iruña, 24 April 2018 1 Assumptions All models rely on assumptions Log-transformation allows for additive effects required in
More information(Regulatory) views on Biomarker defined Subgroups
(Regulatory) views on Biomarker defined Subgroups Norbert Benda Disclaimer: Views expressed in this presentation are the author's personal views and not necessarily the views of BfArM Biomarker defined
More informationWorking with Difficult Investigators
Vol. 8, No. 9, September 2012 Happy Trials to You Working with Difficult Investigators By Rachel Garman and Norman M. Goldfarb Disclaimer: All names have been changed to protect the difficult. Principal
More informationWorking with Clients with Personality Disorders. Core Issues of All Personality Disorders. High Conflict Personality Disorders
Working with Clients with Personality Disorders AFCC Webinar July 18, 2018 Bill Eddy, LCSW, Esq. Copyright 2018 High Conflict Institute www.highconflictinstitute.com Core Issues of All Personality Disorders
More informationPolicy Gradients. CS : Deep Reinforcement Learning Sergey Levine
Policy Gradients CS 294-112: Deep Reinforcement Learning Sergey Levine Class Notes 1. Homework 1 due today (11:59 pm)! Don t be late! 2. Remember to start forming final project groups Today s Lecture 1.
More informationPCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/pcsk9-antibodies-dyslipidemia-efficacy-safety-and-nonlipid-effects/8335/
More informationA Guide to Help You Reduce and Stop Using Tobacco
Let s Talk Tobacco A Guide to Help You Reduce and Stop Using Tobacco Congratulations for taking this first step towards a healthier you! 1-866-710-QUIT (7848) albertaquits.ca It can be hard to stop using
More informationThe first section of this booklet will help you think about what alcohol can do to your health.
6 5 4 3 2 Your doctor or health worker has advised you that you are drinking at a level which can cause problems. Do you think your health or any part of your life may suffer because of your drinking?
More informationPolicy Gradients. CS : Deep Reinforcement Learning Sergey Levine
Policy Gradients CS 294-112: Deep Reinforcement Learning Sergey Levine Class Notes 1. Homework 1 milestone due today (11:59 pm)! Don t be late! 2. Remember to start forming final project groups Today s
More informationPATIENT STUDY INFORMATION LEAFLET
PATIENT STUDY INFORMATION LEAFLET BOOKLET 1 You are invited to take part in this research study. Before you decide, it is important for you to understand why the research is being done and what it will
More informationIncrease your Rapport skills in Health and Well-being, Business and Relationships
Increase your Rapport skills in Health and Well-being, Business and Relationships by Nadine K. Cooper Present State Desired State RESOURCES What you do speaks louder than what you say! NLP Individual Ecology
More informationQuestion: I m worried my child is using illegal drugs, what should I do about it?
Question: I m worried my child is using illegal drugs, what should I do about it? Answer: Many parents worry about whether their son or daughter is using illegal drugs and what they should do about it.
More informationAn introduction to Quality by Design. Dr Martin Landray University of Oxford
An introduction to Quality by Design Dr Martin Landray University of Oxford Criteria for a good trial Ask an IMPORTANT question Answer it RELIABLY Quality Quality is the absence of errors that matter to
More informationImprove Patient Adherence with Motivational Interviewing
Improve Patient Adherence with Motivational Interviewing Bruce A. Berger, PhD President, Berger Consulting, LLC and Professor Emeritus, Auburn University Harrison School of Pharmacy bbergerconsulting@gmail.com
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationPDRF About Propensity Weighting emma in Australia Adam Hodgson & Andrey Ponomarev Ipsos Connect Australia
1. Introduction It is not news for the research industry that over time, we have to face lower response rates from consumer surveys (Cook, 2000, Holbrook, 2008). It is not infrequent these days, especially
More informationWho will benefit from using this app?
INSTRUCTIONS for THE MINDFUL EATING COACH APP (available at Apple Store) (These instructions provide more detail than what is currently in the app under the Coaching tab) Who will benefit from using this
More informationOptimizing Communication of Emergency Response Adaptive Randomization Clinical Trials to Potential Participants
1. Background The use of response adaptive randomization (RAR) is becoming more common in clinical trials (Journal of Clinical Oncology. 2011;29(6):606-609). Such designs will change the randomization
More informationWhat are your concerns? 3. Information about diabetes and treatment 5. About insulin therapy 6. Knowing your blood sugar 7. What are your choices?
Contents What are your concerns? 3 Information about diabetes and treatment 5 About insulin therapy 6 Knowing your blood sugar 7 What are your choices? 9 Advantages and disadvantages of the treatment options
More informationKaiser Permanente Colorado
Health and Wellness Newsletter December 2011 Depression Who is at risk for depression? Kaiser Permanente Colorado Depression is more common than many people realize. Often, people who become depressed
More informationCarotid Ultrasound Scans for Assessing Cardiovascular Risk
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/carotid-ultrasound-scans-for-assessing-cardiovascularrisk/4004/
More informationMS&E 226: Small Data
MS&E 226: Small Data Lecture 10: Introduction to inference (v2) Ramesh Johari ramesh.johari@stanford.edu 1 / 17 What is inference? 2 / 17 Where did our data come from? Recall our sample is: Y, the vector
More informationICH E9 (R1) Addendum on Estimands and Sensitivity Analysis
ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis Rob Hemmings Mouna Akacha MHRA + ICH E9 (R1) Expert Working Group Novartis 1 Disclaimer (I) Not a statistical topic This impacts every clinical
More informationSTROKE INTRODUCTION OBJECTIVES. When the student has finished this module, he/she will be able to:
STROKE INTRODUCTION Stroke is the medical term for a specific type of neurological event that causes damage to the brain. There are two types of stroke, but both types of stroke cause the same type of
More informationSample Size and Power
Sample Size and Power Chapter 22, 3 rd Edition Chapter 15, 2 nd Edition Laura Lee Johnson, Ph.D. Associate Director Division of Biostatistics III Center for Drug Evaluation and Research US Food and Drug
More informationLecture 2: Learning and Equilibrium Extensive-Form Games
Lecture 2: Learning and Equilibrium Extensive-Form Games III. Nash Equilibrium in Extensive Form Games IV. Self-Confirming Equilibrium and Passive Learning V. Learning Off-path Play D. Fudenberg Marshall
More informationInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
Final Concept Paper E9(R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials dated 22 October 2014 Endorsed
More informationCardiovascular Controversies: Exploring the ACC and AHA Guidelines on the Treatment of Blood Cholesterol
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials
DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop
More informationClinical trial design issues and options for the study of rare diseases
Clinical trial design issues and options for the study of rare diseases November 19, 2018 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationFramework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
Framework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM) MRD in Multiple Myeloma Team Biomarker Qualification Workshop Framework
More informationLecture 2. Key Concepts in Clinical Research
Lecture 2 Key Concepts in Clinical Research Outline Key Statistical Concepts Bias and Variability Type I Error and Power Confounding and Interaction Statistical Difference vs Clinical Difference One-sided
More informationThe Physician, the Community and Health Care Reform
International Journal of Health Sciences Published by American Research Institute for Policy Development URL: http://www.healthe-link.com/aripd/ijhs/ijhsbofv3n1p1_7.pdf CDC grant award H75DP002301-01 Healthy
More informationOptions in HIV Prevention A Participant-Centered Counseling Approach
Options in HIV Prevention A Participant-Centered Counseling Approach Options Counseling Flipchart, Version 3.0, 10 Oct 2017 Enrollment Visit Welcome and thank you! 3 HOPE Adherence Counseling CHOICE: Helping
More informationWORTH A CLOSER LOOK.
A birth control pill... WORTH A CLOSER LOOK. Ask your healthcare provider about. Please see Important Safety Information including Boxed Warning throughout this brochure and on pages 4 and 5. offers a
More information